{"entity":{"id":"viper-102","kind":"drug","name":"VIPER-102","aka":[],"tldr":"VIPER-102 is an experimental CAR-T cell therapy from Vittoria Biotherapeutics, in preclinical development for solid tumours.","summary":"VIPER-102 is a CAR-T cell therapy from Vittoria Biotherapeutics. CAR T cells against an undisclosed solid tumour antigen that the company says is over-expressed by malignant cells and compartmentalised in healthy tissue. Its furthest stage is preclinical development, for solid tumours. No clinical trial naming it is registered on ClinicalTrials.gov. IND-enabling studies per pipeline page. It has not been shown to work in people.","status":"preclinical","asOf":"2026-11-03","links":[{"label":"Vittoria Biotherapeutics: vittoriabio.com","url":"https://vittoriabio.com/pipeline/"},{"label":"Vittoria Biotherapeutics: vittoriabio.com","url":"https://vittoriabio.com/pipeline/"}],"tags":["pipeline"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["vittoria-biotherapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"VIPER-102","modality":"CAR-T cell therapy","mechanism":"CAR T cells against an undisclosed solid tumour antigen that the company says is over-expressed by malignant cells and compartmentalised in healthy tissue.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/viper-102/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"vittoria-biotherapeutics","kind":"company","name":"Vittoria Biotherapeutics","route":"/companies/vittoria-biotherapeutics/"}]}}